June 19, 2017
Novartis’s division wins EC approval for its cancer drug
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: blood cancer
February 6, 2017
Kiadis Pharma in phase 3 with leukemia drug ATIR101
Kiadis Pharma has started its phase III trial with its major products for blood cancer hematopoietic stem cell transplantation (HSCT) ATIR101.
December 21, 2016
Kiadis Pharma provides update on Phase II trial with cancer drug
Kiadis Pharma has announced an update on the second dose Phase II trial with ATIR101 (CR-AIR-008 ).